Send to

Choose Destination
J Bone Miner Res. 2010 Mar;25(3):673-5. doi: 10.1002/jbmr.44.

Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin.

Author information

Department of Endocrinology and Metabolism, Laboratory for Molecular Endocrinology (KMEB), Medical Biotechnology Centre, University of Southern Denmark, Odense, Denmark.

Erratum in

  • J Bone Miner Res. 2010 Aug;25(8):1896.


The Lrp5 gene is a major determinant of bone mass accrual. It has been demonstrated recently to achieve this function by hampering the synthesis of gut-derived serotonin, which is a powerful inhibitor of bone formation. In this study we analyzed plasma serotonin levels in patients with a high-bone-mass (HBM) phenotype owing to gain-of-function mutation of Lrp5 (T253I). A total of 9 HBM patients were compared with 18 sex- and age-matched controls. In HBM patients, the serotonin concentrations in platelet-poor plasma were significantly lower than in the controls (mean +/- SEM: 2.16 +/- 0.28 ng/mL versus 3.51 +/- 0.49 ng/mL, respectively, p < .05). Our data support the hypothesis that circulating serotonin levels mediate the increased bone mass resulting from gain-of-function mutations in Lrp5 in humans.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center